Search research articles
Contact Us
Filters
Showing results (41-50 of 61) with videos related to
Page
of 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2025
Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial
Jean-Marie Michot, Serge Bologna, Jean-Noël Bastie, et al.
Blood
|
November 18, 2023
The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients
Hervé Ghesquières, Daphné Krzisch, Emmanuelle Nicolas-Virelizier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2022
Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study
René-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2021
Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older
Lucie Oberic, Frederic Peyrade, Mathieu Puyade, et al.
Cancers
|
September 28, 2021
Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years
Maxime Jullien, Benoit Tessoulin, Hervé Ghesquières, et al.
Blood Advances
|
December 8, 2022
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
Raphaelle Aubrais, Krimo Bouabdallah, Loic Chartier, et al.
Leukemia
|
October 7, 2018
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study
Roch Houot, Guillaume Cartron, Fontanet Bijou, et al.
Blood
|
July 3, 2016
Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas
David Vallois, Maria Pamela D Dobay, Ryan D Morin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2022
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial
Luc-Matthieu Fornecker, Julien Lazarovici, Igor Aurer, et al.
British Journal of Haematology
|
March 3, 2025
A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis
Pablo Mozas, Romain Ould Ammar, Loïc Chartier, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 61) with videos related to
Sort By:
Page
of 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2025
Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial
Jean-Marie Michot, Serge Bologna, Jean-Noël Bastie, et al.
Blood
|
November 18, 2023
The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients
Hervé Ghesquières, Daphné Krzisch, Emmanuelle Nicolas-Virelizier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2022
Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study
René-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2021
Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older
Lucie Oberic, Frederic Peyrade, Mathieu Puyade, et al.
Cancers
|
September 28, 2021
Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years
Maxime Jullien, Benoit Tessoulin, Hervé Ghesquières, et al.
Blood Advances
|
December 8, 2022
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
Raphaelle Aubrais, Krimo Bouabdallah, Loic Chartier, et al.
Leukemia
|
October 7, 2018
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study
Roch Houot, Guillaume Cartron, Fontanet Bijou, et al.
Blood
|
July 3, 2016
Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas
David Vallois, Maria Pamela D Dobay, Ryan D Morin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2022
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial
Luc-Matthieu Fornecker, Julien Lazarovici, Igor Aurer, et al.
British Journal of Haematology
|
March 3, 2025
A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis
Pablo Mozas, Romain Ould Ammar, Loïc Chartier, et al.
Page
of 7